Mar
1
2022
On demand

Rethink CAR T cell therapy with a scalable RNA lipid nanoparticle platform

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Advance T cell therapy research into the clinic with a novel lipid nanoparticle (LNP) platform. This platform enables cell therapy researchers to establish a clinically-relevant method for ex vivo gene delivery and editing Genetically modifying immune cells against tumors is a promising anti-cancer therapy. However, current gene delivery methods have significant challenges, hindering further innovations in cell therapies. Non-viral electroporation method can be harsh on cells, making it difficult to generate quality cells at high yields, whereas conventional viral vector delivery method is expensive and cumbersome to manufacture.GenVoy-ILM™ T Cell Kit for mRNA, a first-to-market lipid nanoparticle reagent kit, overcomes these limitations to enable RNA delivery into human primary T cells with high efficiency while maintaining high cell viability. This kit can be easily tuned and scaled across the NanoAssemblr® NxGen microfluidic platform from discovery to the clinic. 

  • Challenges with current ex vivo gene delivery and editing strategies for cell therapies
  • Potential of RNA-LNPs in cell therapies
  • Introduction of GenVoy™ lipid nanoparticle delivery and NanoAssemblr® microfluidic platform
  • Latest proof-of-concept study results

Angela Zhang, PhD

Senior Product Manager, Precision Nanosystems

Dr. Angela Zhang is a Senior Product Manager at Precision NanoSystems Inc. After obtaining her PhD in Immunology at the University of Toronto, Angela had various roles in the immunotherapy and epithelial stem cell biology areas prior to joining Precision NanoSystems in 2020. She is passionate about enabling broader adoption of lipid nanoparticles by researchers and drug developers, particularly those working in cell therapies.

Reka Geczy, PhD

Product Development Scientist, Precision Nanosystems

Reka holds a PhD in Pharmaceutical Sciences from the University of British Columbia with high impact publications at the interface of microfluidics and drug delivery. After her postdoc at the University of Copenhagen, she joined Precision NanoSystems. as a Product Development Scientist. Her team is developing potent and efficient lipid nanoparticle compositions for cell therapy, currently focusing on CAR T cancer therapy.

SPEAKERS

Angela Zhang, PhD
Senior Product Manager at Precision NanoSystems Inc
Reka Geczy, PhD
Product Development Scientist at Precision NanoSystems Inc

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
36
Days
7
Hrs
40
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
14
Days
7
Hrs
40
Min
Register

Improving T cell therapy manufacturing processes with automation and...

E Zynda, PhD
Evan Zynda, PhD
Evan Zynda, PhD
Staff Scientist, Cell Biology at Thermo Fisher Scientific
26 May 2022
9
Days
7
Hrs
40
Min
Register

Streamlined workflow solutions for cell and gene therapy analytics

A Graband
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
24 May 2022
7
Days
7
Hrs
40
Min
Register

Strategic partnering to enable cell therapy commercialization

J Smith
X de Mollerat du Jeu
Jenessa Smith
Jenessa Smith
Associate Director of Process Development at ArsenalBio
Xavier de Mollerat du Jeu
Xavier de Mollerat du Jeu
Senior Director, R&D, Cell and Gene Therapy at Thermo Fisher Scientific
12 May 2022
Watch now